Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

Author's Avatar
Jul 02, 2022

Top-line data anticipated in the Q3 2022